Silence Therapeutics PLC(SLN) - 2023 Q4 - Annual Report

Clinical Study Results - Silence Therapeutics announced positive topline 36-week data from the ALPACAR-360 phase 2 study of zerlasiran, showing highly significant reductions in lipoprotein(a) (Lp(a)) levels[1]. - The study involved 178 subjects with baseline Lp(a) levels at or over 125 nmol/L, indicating a high risk of atherosclerotic cardiovascular disease (ASCVD) events[1]. - Median baseline Lp(a) was approximately 215 nmol/L, with a median percentage reduction in Lp(a) of 90% or greater observed for both 300 mg and 450 mg doses at week 36[2]. - No new safety concerns were identified during the treatment period, supporting the safety profile of zerlasiran[2]. - Silence plans to report topline 48-week data from the study in the second quarter of 2024[4]. - The ongoing 60-week study will evaluate secondary endpoints, including changes in Lp(a) from baseline to 48 weeks and 60 weeks[3]. Company Focus and Collaborations - Silence Therapeutics is focused on developing RNA interference-based medicines to address significant unmet medical needs, particularly in cardiovascular disease[5]. - The company maintains ongoing research collaborations with AstraZeneca and Hansoh Pharma, enhancing its development capabilities[5]. Forward-Looking Statements - Forward-looking statements indicate potential risks and uncertainties regarding clinical and commercial prospects, regulatory approvals, and future data reports[6]. - Silence cautions stakeholders not to place undue reliance on forward-looking statements, which reflect the company's views as of the announcement date[6].